Genetix Biotherapeutics Inc. (formerly bluebird bio, Inc.)

Privately held: no public share price

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Approved
Beta-globin gene addition (betaA-T87Q)Gene therapy / editing
Sickle Cell Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
May 2027 (1)
Lovotibeglogene autotemcel (Lyfgenia)Phase 3Sickle Cell Disease
Est. primary completion 2027-05 · NCT04293185 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.